Refractory Acute Lymphoblastic Leukemia (ALL)

DBCOND0069492Hemic and Lymphatic DiseasesImmunoproliferative Disorders

Refractory Acute Lymphoblastic Leukemia (ALL) is the indication for 2 drugs in DrugBank. It is covered by 2 curated, structured indications.

Also known as
Acute lymphocytic leukaemia refractory · refractory Acute lymphoblastic leukaemia · Acute lymphocytic leukemia refractory · Refractory Acute Lymphoblastic Leukemia · Acute Lymphoblastic Leukemia, Refractory
Classified under
Indicated drugs

Resolves to

Vocabularies
MedDRA10076866UMLSC4049242

What you can answer from here — as of November 01, 2026

2Indicated drugsWith each drug's targets and mechanism
Listed above
2Structured indicationsPopulation, line of therapy, route and combination as fields, not prose
Sign in
120Clinical trialsPhase, status and sponsor resolved per trial
Sign in

Which approved drugs for Refractory Acute Lymphoblastic Leukemia (ALL) share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In